Manufacturability and the Winners in Advanced Therapies

Alan Boyd, a veteran in drug development, highlights the journey of R&D over the past 40 years, advocating for addressing manufacturing challenges in cell and gene therapies. He observes a pivotal shift from discovery to manufacturing as the core issue in modern therapeutics, emphasizing the need for expertise in this area. Boyd also reflects on evolving funding landscapes and trends, stressing the importance of developing scalable technologies and addressing broader patient populations, especially in developing countries.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine